{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["N/A"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001005819"],"sample_count":["8"],"description":["EGA dataset EGAD00001005819"],"repository":["EGA"],"title":["Spatial whole exome sequencing of metastatic melanoma"],"name_synonyms":["Vasp, VASP, Data Set., DmelCG15112, ENHANCER OF ATNSI ACTIVITY, MENA, NDPP1, l(2)02029, Enb, enb, ENA, Ena, CG15112, ENA/VASP"],"description_synonyms":["Bru, PhrB photolyase activity, Procedures, Raw, determination, Complete Exome, Neoplasms, Benign Neoplasm, photoreactivating enzyme activity, Tumor, pigmented epithelium, Malignant, HiSeq 2000, Medical Specialties, Speciality, Techniques, RPL23, Medical Specialities, Method, Specialities, Studies, 3, Whole Transcriptome, Transcriptome Sequencing, stratum pigmentosa retinae, NUP96, Del(8)44H, cytopathology, epithelium, Medical, Technique, Titan, treatment, Svc, Ly101, WES, Complete, MOS3, anatomical systems, Insurance Medicine, Exome Sequencings, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Biopsies, PRECOCIOUS, Malignancy, Complete Exome Sequencing, Whole Transcriptome Sequencing, pigmented retina, inhibiteur, F23A5.3, nucleic acid library construction, nucleic acid library preparation, procedures, CD279, Sequencing, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, Study, Neoplasias, Whole Exome, drugs, Pdc1, inhibidor, data processing, Methodological Studies, medicine, malignant neoplasm, Clients, Whole, disease management, Therapies, Medicine, L17, Malignancies, Medicines, Insurance, metastatic malignant melanoma, F23A5_3, HHT1, Cancer, Tumors, inhibitors, Therapy, PRE, Specialties, Complete Exome Sequencings, Malignant Neoplasm, SLEB2, Edg, Medical Specialty, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Exome, l17, inhibitor, Procedure, Client, Medical Speciality, Exome Sequencing, MODIFIER OF SNC1, MT, Benign, rpl17a, retinal pigment, pd-1, chemical analysis, deoxyribonucleic photolyase activity, Specialty, Neoplasm, dipyrimidine photolyase (photosensitive), metastatic melanoma, techniques, END, retinal pigment layer, PD1, PD-1, antagonists, Phoebe, Complete Transcriptome, primary cancer, RPE, Complete Transcriptome Sequencing, Col4a-1, histopathology, photolyase activity, library construction, 60S ribosomal protein L23, Benign Neoplasms, rpl23, patient, Methodological, Cancers, Methodological Study, Treatments, malignant tumor, hPD-1, p. pigmentosa retinae, Insurance Medicines, data analysis, phr A photolyase activity, hPD-l, DNA-photoreactivating enzyme, Patient, antagonists and inhibitors, Therapeutic, hSLE1, rpl17, Whole Exome Sequencing, Treatment, deoxyribonucleate pyrimidine dimer lyase (photosensitive), assay, biopsy, ORW1, Transcriptome Sequencings, Neoplasia, methodology, Malignant Neoplasms."],"additional_accession":[]},"is_claimable":false,"name":"ena-DATASET-MDACC-27-01-2020-21:07:34:858-257 - samples","description":"We performed whole exome sequencing of 8 samples derived from a patient with metastatic melanoma. These represent six different regions of a metastatic melanoma biopsy that was treated with anti-PD-1 inhibitor, one pre-treatment biopsy that was treatment naive and one post-PD-1 inhibitor treated lesion. Exome sequencing data was generated using methods as previously described, including library preparation using the Agilent SureSelect XT Target Enrichment protocol (#5190-8646) prior to sequencing on an Illumina HiSeq 2000/2500 v3 system using 76bp paired-end reads. Raw sequencing data was then processed using Saturn V, the next generation sequencing data processing and analysis pipeline developed by the Department of Genomic Medicine at the UT MD Anderson Cancer Center.","dates":{"updated":"2020-03-05 08:39:38"},"accession":"EGAD00001005819","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAC00001001446","EGAS00001003292"]}}